TrialBMJ open ophthalmology2023

Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration: 1-year and switching results of a phase 3 clinical trial.

SriniVas R Sadda et al.PubMed ↗Publisher ↗

No numbers read from the abstract.